Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.
Vijay Srinivasan, MBBS, MD, works in research and quality improvement programs dealing with critical illness endocrinopathies and nutrition to improve outcomes in critically ill children. His research focuses on stress hyperglycemia with tight glycemic control and nutrition therapy.
Dr. Wallis explores socio-demographic disparities in the diagnosis of developmental disorders and autism spectrum disorder (ASD), and the process of screening for these conditions in pediatric primary care. She aims to develop and test strategies to improve developmental outcomes for all children and to bridge gaps in identification and care for low-income and minority children and girls with developmental delays and autism spectrum disorder.
Dr. Maude focuses on novel therapies for high-risk and relapsed pediatric acute lymphoblastic leukemia (ALL). She aims to identify new pediatric ALL treatments that are more effective, less toxic, and exhibit fewer side effects than existing cancer therapies.
Dr. Teachey's research focuses on investigating novel therapeutics for children with white blood cell diseases, including ALL and a rare autoimmune disease called Autoimmune Lymphoproliferative Syndrome (ALPS). His research in ALL focuses on studying leukemic cells from children with high-risk disease.
Dr. Sengupta is a neonatologist and physician scientist with a long-standing interest in lung health. She studies the mechanisms of circadian regulation of lung inflammation, injury, and repair; and the effect of early life exposures on development and function of pulmonary circadian networks in adulthood.
Dr. Rheingold's research interests center on acute lymphocytic leukemia, and she serves on the Children's Oncology Group's Relapsed ALL, Infant ALL, and Complementary Therapies committees. In addition, she is investigates complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education, and rare childhood tumors.
Dr. Seif's research centers on manipulating the human innate and immune systems to treat children with acute lymphoblastic leukemia (ALL). The long-term goal of her research is to identify innate and adaptive immune mechanisms that can be used to treat pediatric ALL more effectively, and with less toxicity, than existing therapies.
Dr. Grupp develops and conducts preclinical testing of engineered cell therapies and signal transduction inhibitors in leukemia, in pediatric immunotherapy trials, and in the manufacture and use of cellular therapeutics in preclinical, good manufacturing practices, and clinical trial settings. Dr. Grupp leads most CTL019 (CD19 CAR) clinical trials, and his colleagues are the global leaders in highly active CAR T cell therapy.